Oriptan (Sumatriptan)

Sumatriptan, the active ingredient in Oriptan, is a selective serotonin 5‑HT1 receptor agonist presented as a tablet for oral use. It is employed to treat acute migraine attacks and cluster headache episodes in adults. GNH USA supplies Oriptan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Sumatriptan acts on the serotonergic pathway to provide rapid relief of specific headache disorders.

Migraine: alleviates pain and associated symptoms of acute migraine attacks. Cluster headache: aborts acute cluster headache episodes. Migraine with aura: reduces headache intensity and associated visual disturbances during an attack.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in extremities - Warmth or flushing sensation - Nausea or abdominal pain - Dizziness or light‑headedness - Fatigue or drowsiness

Serious or Rare Side Effects: - Coronary vasospasm or myocardial ischemia - Severe hypertension or hypertensive crisis - Serotonin syndrome when combined with other serotonergic agents - Anaphylactic or severe allergic reactions - Acute skin reactions such as Stevens‑Johnson syndrome - Persistent or worsening headache despite treatment

Before using Sumatriptan, consider the following safety measures.

Cardiovascular disease: avoid if you have uncontrolled angina, recent myocardial infarction, or severe coronary artery disease. Serotonergic drugs: do not combine with MAO inhibitors, SSRIs, SNRIs, or other triptans due to serotonin syndrome risk. Pregnancy and lactation: use only if clearly needed; limited safety data are available. Age restrictions: not recommended for children under 12 years of age. Renal/hepatic impairment: dose adjustment may be required in moderate to severe dysfunction. Store at ambient temperature: keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Sumatriptan may interact with several medication classes.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstrictive effects. - Certain antihypertensives (e.g., ergotamine): heightened cardiovascular risk.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise sumatriptan plasma levels. - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Oral contraceptives: may slightly increase migraine frequency; monitor response.